Dietary counselling to increase soluble fibre in patients with gynaecological cancers undergoing pelvic radiotherapy: A feasibility study
Journal of Human Nutrition and Dietetics · 2025
DOI: 10.1111/jhn.13402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Nutrition and Dietetics, 2025. Verfasst von Emilie Croisier und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Human Movement & Nutrition Sciences, University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Dietary Fiber, Feasibility Studies, Genital Neoplasms, Female, Counseling. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Australian Government Research Training Programme (RTP).
Abstract (Originalsprache)
Background
This study aimed to determine the feasibility of increasing soluble fibre intake via dietary counselling to improve gastrointestinal toxicity and quality of life in patients with gynaecological cancers undergoing pelvic radiotherapy without adverse consequences on radiation treatment (RT) delivery accuracy.
Methods
A single‐arm, single‐centre intervention feasibility trial included patients with gynaecological cancers undergoing pelvic RT ± chemotherapy at a tertiary hospital. Participants were provided weekly dietary counselling over the duration of their RT (5–6 weeks) to increase soluble fibre intake incrementally each week. Stakeholder surveys were also completed.
Results
In total, 9 of 14 eligible patients participated (55 years old [SD 13.2], diagnosis: cervical [ n = 3], endometrial/uterine [ n = 5] and vaginal [ n = 1]), with the majority categorised as low fibre consumers at baseline ( n = 6). On average, soluble fibre intake increased by 150% throughout treatment. There were no adverse events or major adjustments required for RT delivery. There were improving trends in the functional subset identified. Results may be confounded by the sample size resulting from limited eligibility ( n = 14) and a high attrition rate ( n = 4).
Conclusions
Most participants successfully increased their soluble fibre intake throughout treatment, without significant adverse events noted for RT delivery accuracy. These results provide preliminary data to calculate the sample size required to produce meaningful effect sizes. However, this study highlighted challenges in participant recruitment and retention, with limited organisational support and perceived compatibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Human Movement & Nutrition Sciences, University of Queensland, Brisbane, Queensland, Australia.
- Dietetics & Food Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Radiation Therapy, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Radiation Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, Australia.
Förderung
- Australian Government Research Training Programme (RTP)
Zitieren
APA
Croisier, E., Brown, T., Grigg, A., Chan, P., & Bauer, J. (2025). Dietary counselling to increase soluble fibre in patients with gynaecological cancers undergoing pelvic radiotherapy: A feasibility study. Journal of Human Nutrition and Dietetics. https://doi.org/10.1111/jhn.13402
Vancouver
Croisier E, Brown T, Grigg A, Chan P, Bauer J. Dietary counselling to increase soluble fibre in patients with gynaecological cancers undergoing pelvic radiotherapy: A feasibility study. Journal of Human Nutrition and Dietetics. 2025. doi:10.1111/jhn.13402
BibTeX
@article{Croisier2025,
author = {Croisier, Emilie and Brown, Teresa and Grigg, Alice and Chan, Philip and Bauer, Judy},
title = {Dietary counselling to increase soluble fibre in patients with gynaecological cancers undergoing pelvic radiotherapy: A feasibility study},
journal = {Journal of Human Nutrition and Dietetics},
year = {2025},
doi = {10.1111/jhn.13402}
}
EUVIMED